ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$23.64 USD
-0.40 (-1.66%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $23.64 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, ACADIA Pharmaceuticals Inc. has a market cap of $4.02B, which represents its share price of $24.04 multiplied by its outstanding shares number of 167.36M. As a mid-cap company, ACAD's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ACAD 23.64 -0.40(-1.66%)
Will ACAD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Other News for ACAD
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference | ...
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer | ACAD Stock News
10 Health Care Stocks Whale Activity In Today's Session
Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) | ACAD Stock News